XGN News and Press, Exagen Inc. From 10/23/25

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025...

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President...

2025-09-13 08:29:57 ET Exagen Inc. ( XGN ) stock is having an excellent year, now trading at its 52-week highs, levels last attained during the beginning of January 2022. XGN stock had a rough and very slow patch from October 2022 to July 2024, and now it looks like it's back on tra...

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45 th Annual Growth Co...

2025-07-29 15:10:18 ET More on Exagen Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript Exagen GAAP EPS of -$0.21 misses by $0.06, revenue of $17.2M beats by $0.89M Exagen prices public offering of common st...

2025-07-29 15:09:37 ET Exagen Inc. (XGN) Q2 2025 Earnings Conference Call July 29, 2025, 08:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Douglas - Investors Relations Officer ...

2025-07-29 08:04:53 ET More on Exagen Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript Exagen prices public offering of common stock Exagen prices public offering of common stock Seeking Alpha’s Quant Rating on Exagen Historical earnings data...

CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates. Q2 2025 Highlights and Recent Corporate Updates: ...

AstraZeneca PLC (AZN) is expected to report $1.09 for Q2 2025 Commvault Systems Inc. (CVLT) is expected to report $0.47 for Q1 2026 Ares Capital Corporation (ARCC) is expected to report $0.51 for Q2 2025 Northwest Bancshares Inc. (NWBI) is expected to report $0.29 for Q2 2025 Repl...

Exagen Inc. (XGN) is expected to report $-0.18 for Q2 2025